 Cancer drug resistance is a major obstacle in medical oncology that arises prior to or as a result of therapy, involving alterations in drug transport and metabolism, mutation and amplification of drug targets, genetic rewiring leading to impaired apoptosis, tumor heterogeneity, and multi-drug resistance. Understanding these processes can inform the development of new cancer therapies. This article was authored by Hibbe Ezeredein and Katharine Borden.